

SCOUT-HCM

Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy

OBJECTIVE: To evaluate the safety and efficacy of mavacamten in adolescent patients (12 to < 18 years of age) with class II or III obstructive hypertrophic cardiomyopathy (HCM)

STUDY DESIGN: International (28 sites in 9 countries), double-blind, placebo-controlled, randomized controlled trial, N=44

CONCLUSIONS: Treatment with mavacamten was associated with a significantly greater reduction in Valsalva-provoked left ventricular outflow tract gradient and a similar safety profile compared with placebo over 28 weeks.



American
Heart
Association.